BioCentury | Apr 9, 2021
Product Development

Macrophage therapies to watch at AACR

Macrophage cell therapies may make headlines this weekend as the first CAR macrophage data in an immunocompetent animal model read out at AACR, but the conference will also showcase a spate of other strategies...
BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

BioCentury’s analysis of this year’s AACR meeting unearths orthogonal approaches to high-wattage targets KRAS and TIGIT, details on allogeneic and personalized cell therapies, and targeted protein degradation players beyond the usual suspects. In the run-up...
BioCentury | Mar 13, 2021
Translation in Brief

NIH identifies antisense oligos to treat progeria; plus epigenetic gene therapies for chronic pain and Cend’s pancreatic cancer therapy

Antisense oligonucleotides to treat progeriaTwo NIH teams, one led by NIH director Francis Collins, discovered antisense oligonucleotides (ASOs) against the LMNA gene to treat Hutchinson-Gilford progeria syndrome (HGPS). The disorder is caused by progerin, a...
BioCentury | Mar 12, 2021
Product Development

Korea Spotlight: How OliX is spreading its siRNA beyond Korea’s borders

The launch of an mRNA subsidiary is the latest move by RNAi company OliX to build upon its trio of partnerships and bicoastal beachhead of U.S. offices to realize its global ambitions. OliX Pharmaceuticals...
BioCentury | Mar 11, 2021
Product Development

Bluebird builds the case against gene therapy cancer link

Bluebird is seeking to resume clinical development and marketing of products based on the BB305 lentiviral vector after largely ruling it out as the cause of cancer in a clinical trial participant, but the case...
BioCentury | Mar 6, 2021
Finance

With $106M series C, Tenaya will bring AAV manufacturing in-house

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine platforms for heart disease.  Tenaya Therapeutics...
BioCentury | Mar 5, 2021
Tools & Techniques

Flexible platform: how NCI’s Sharpless thinks COVID variants could boost personalized therapies

As regulators embrace platform technologies to rapidly update COVID-19 vaccines, they are laying the groundwork for personalized cancer and rare disease therapies, according to NCI Director Ned Sharpless....
BioCentury | Mar 3, 2021
Product Development

Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

FogPharma will use its venBio-led $107 million series C round to bring its lead program, a cell-permeable CTNNB1 antagonist, into the clinic for cancer. The company, helmed by Chairman, President...
BioCentury | Mar 3, 2021
Product Development

With Kymera’s clinical debut, targeted protein degradation gets its first RCT

As Kymera becomes the second company to bring a targeted protein degrader to the clinic, the company’s choice to start outside oncology is enabling it to gather a broader array of data than Arvinas’ single-arm,...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
Items per page:
1 - 10 of 2713
BioCentury | Apr 9, 2021
Product Development

Macrophage therapies to watch at AACR

Macrophage cell therapies may make headlines this weekend as the first CAR macrophage data in an immunocompetent animal model read out at AACR, but the conference will also showcase a spate of other strategies...
BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

BioCentury’s analysis of this year’s AACR meeting unearths orthogonal approaches to high-wattage targets KRAS and TIGIT, details on allogeneic and personalized cell therapies, and targeted protein degradation players beyond the usual suspects. In the run-up...
BioCentury | Mar 13, 2021
Translation in Brief

NIH identifies antisense oligos to treat progeria; plus epigenetic gene therapies for chronic pain and Cend’s pancreatic cancer therapy

Antisense oligonucleotides to treat progeriaTwo NIH teams, one led by NIH director Francis Collins, discovered antisense oligonucleotides (ASOs) against the LMNA gene to treat Hutchinson-Gilford progeria syndrome (HGPS). The disorder is caused by progerin, a...
BioCentury | Mar 12, 2021
Product Development

Korea Spotlight: How OliX is spreading its siRNA beyond Korea’s borders

The launch of an mRNA subsidiary is the latest move by RNAi company OliX to build upon its trio of partnerships and bicoastal beachhead of U.S. offices to realize its global ambitions. OliX Pharmaceuticals...
BioCentury | Mar 11, 2021
Product Development

Bluebird builds the case against gene therapy cancer link

Bluebird is seeking to resume clinical development and marketing of products based on the BB305 lentiviral vector after largely ruling it out as the cause of cancer in a clinical trial participant, but the case...
BioCentury | Mar 6, 2021
Finance

With $106M series C, Tenaya will bring AAV manufacturing in-house

With $106 million in new series C funding, Tenaya will internalize its AAV manufacturing capabilities and continue to advance its suite of gene therapy, cellular regeneration and precision medicine platforms for heart disease.  Tenaya Therapeutics...
BioCentury | Mar 5, 2021
Tools & Techniques

Flexible platform: how NCI’s Sharpless thinks COVID variants could boost personalized therapies

As regulators embrace platform technologies to rapidly update COVID-19 vaccines, they are laying the groundwork for personalized cancer and rare disease therapies, according to NCI Director Ned Sharpless....
BioCentury | Mar 3, 2021
Product Development

Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

FogPharma will use its venBio-led $107 million series C round to bring its lead program, a cell-permeable CTNNB1 antagonist, into the clinic for cancer. The company, helmed by Chairman, President...
BioCentury | Mar 3, 2021
Product Development

With Kymera’s clinical debut, targeted protein degradation gets its first RCT

As Kymera becomes the second company to bring a targeted protein degrader to the clinic, the company’s choice to start outside oncology is enabling it to gather a broader array of data than Arvinas’ single-arm,...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...
Items per page:
1 - 10 of 2713